西妥昔单抗联合顺铂对鼻咽癌荷瘤裸鼠移植瘤生长作用的影响

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (7): 735-739.

西妥昔单抗联合顺铂对鼻咽癌荷瘤裸鼠移植瘤生长作用的影响

李婧婧^1,2, 冯公侃^1,3, 朱孝峰^1,3, 张晓实^1,2

¹华南肿瘤学国家重点实验室, ²中山大学肿瘤防治中心生物治疗研究中心, ³中山大学肿瘤防治中心实验研究部, 广州 510060, 广东

收稿日期:2008-03-28 修回日期:2008-05-16 出版日期:2008-07-26 发布日期:2020-10-14
通讯作者: 张晓实,男,主任医师,研究方向:肿瘤生物治疗。Tel:020-87343383 E-mail:zxs617@hotmail.com
作者简介:李婧婧,女,硕士,研究方向:肿瘤生物治疗。Tel:020-87343150 E-mail:ljj830606@yahoo.com.cn
基金资助:
国家自然科学基金(30572363);广东省自然科学基金(05001693)

Synergistic anti-tumor activity of cetuximab combining with cisplatin in human nasopharyngeal carcinoma cells

LI Jing-jing^1,2, FENG Gong-li^1,3, ZHU Xiao-feng^1,3, ZHANG Xiao-shi^1,2

¹State Key Laboratory of Oncology in South China, ²Biotherapy Center, ³Department of Experimental Research, Cancer Center of Sun Yat-sen University, Guangzhou 510060, Guangdong, China

Received:2008-03-28 Revised:2008-05-16 Online:2008-07-26 Published:2020-10-14

摘要/Abstract

摘要： 目的:探讨靶向表皮生长因子受体(EGFR)特异性单抗西妥昔单抗单药及与顺铂联合应用对鼻咽癌荷瘤裸鼠移植瘤生长的影响及其可能的作用机制。方法:将鼻咽癌细胞HONE1制成细胞悬液后接种于裸鼠皮下,待成瘤后将裸鼠随机分入4个处理组:生理盐水组、西妥昔单抗组、顺铂组及两药联合组。定期测量每只裸鼠肿瘤最大径和最小径,计算肿瘤体积。用药结束后,处死裸鼠,取出肿瘤组织,称重,计算抑瘤率。用免疫组化方法检测肿瘤组织中磷酸化蛋白激酶B(p-AKT)和人磷酸化细胞外信号调节激酶(p-ERK)表达。结果:与生理盐水组相比,西妥昔单抗单药组肿瘤体积变化及治疗后平均瘤重差异均无统计学意义,顺铂单药组及两药联合组均有抑瘤效应,以两药联合组抑瘤效果尤为显著。免疫组化显示肿瘤组织AKT和ERK磷酸化水平在顺铂处理组上调,而在西妥昔单抗单药及联用组则较低。结论:西妥昔单抗单药对HONE1鼻咽癌荷瘤裸鼠移植瘤的生长无明显影响,但其与顺铂联用可增加顺铂的抑瘤作用。

关键词: 鼻咽癌, 表皮生长因子受体, 西昔妥单抗, 顺铂

Abstract: AIM: To detect the effect of cetuximab combining with cisplatin on growth effect of nasopharyngeal carcinoma xenografts in nude mice and its possible mechanism.METHODS: HONE1 cancer cells were suspended and injected into nude mice subcutaneouly.Then the mice were randomly assigned to four groups: normal saline group, cetuximab group, cisplatin group and combination group.The largest and smallest diameters of athymic mouse tumor were measured regularly, and the tumor volume was calculated.After treatment, all animals were sacrificed, the tumor xenografts were weighed and the inhibitory rates were calculated. The expression of phospho-protein kinase β (p-AKT) and phospho-extracellular signal regulated kinase (p-ERK) were detected with immunohistochemistry.RESULTS: The tumor volume and average weight of cetuximab group after treatment had no significant differentce, there was obvious inhibitory effect in cisplatin group and the combination with cetuximab group, but the later was more significant.The immunohistochemistry assay showed that the expression levels of p-AKT and p-ERK were higher in the samples from the group treated with cisplatin alone compared with saline group, but reduced when treated with cetuximab combined with cisplatin or not.CONCLUSION: The growth of transplantation tumor on HONE1 nasopharyngeal carcinoma bearing cancer in nude mice had no significant effect, it could enhance the antitumor effect of cisplatin on nasopharyngeal carcinoma xenografts.

Key words: nasopharyngeal carcinoma, epidermal growth factor receptor, cetuximab, cisplatin

中图分类号:

R965.1

李婧婧, 冯公侃, 朱孝峰, 张晓实. 西妥昔单抗联合顺铂对鼻咽癌荷瘤裸鼠移植瘤生长作用的影响[J]. 中国临床药理学与治疗学, 2008, 13(7): 735-739.

LI Jing-jing, FENG Gong-li, ZHU Xiao-feng, ZHANG Xiao-shi. Synergistic anti-tumor activity of cetuximab combining with cisplatin in human nasopharyngeal carcinoma cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(7): 735-739.

参考文献

[1] Ciardiello F, TortoraG. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor [J]. Clin Cancer Res, 2001, 7(10): 2958-2970.
[2] Steiner P, Joynes C, Bassi R, et al. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor[J]. Clin Cancer Res, 2007, 13(5): 1540-1551.
[3] Kim S, Prichard CN, Younes MN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice[J]. Clin Cancer Res, 2006, 12(2): 600-607.
[4] Prewett M, Rothman M, Waksal H, et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice[J]. Clin Cancer Res, 1998, 4 (12): 2957-2966.
[5] Teo PM, Kwan WH, Lee WY, et al. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma[J]. Cancer, 1996, 77(12): 2423-2431.
[6] Leong JL, Loh KS, Putti TC, et al. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx[J]. Laryngoscope, 2004, 114(1): 153-157.
[7] Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2004, 59(1): 11-20.
[8] Mai HQ, Zeng ZY, Zhang HZ, et al. Correlation of endothelin A receptor expression to prognosis of nasopharyngeal carcinoma[J]. Ai Zheng, 2005, 24(5): 611-615.
[9] Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic recurrent head and neck cancer: an Eastern Cooperative Oncology Group study[J]. J Clin Oncol, 2005, 23(34): 8646-8654.
[10] Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma[J]. J Clin Oncol, 2005, 23(15): 3568-3576.
[11] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2006, 354(6): 567-578.
[12] Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance[J]. Cancer Lett, 2007, 251(1): 11-16.
[13] Fraser M, Bai T, Tsang BK. AKT promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function[J]. Int J Cancer, 2008, 122(3): 534-546.
[14] Lee MW, Kim DS, Min NY, et al. AKT1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin[J]. Int J Cancer, 2008, 122 (10): 2380-2384.
[15] DeHaan RD, Yazlovitskaya EM, Persons DL. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase[J]. Cancer Chemother Pharmacol, 2001, 48(5): 383-388.
[16] Sung FL, Pang RT, Ma BB, et al. Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma[J]. J Proteome Res, 2006, 5(12): 3260-3267.